The Melanoma Program at VICC
The melanoma program comprises of a diverse group of clinical and laboratory scientists with one common goal: Advancement of the treatment of melanoma. Our commitment to both the clinical and basic science research has allowed us to expand services and treatment options available to melanoma patients. The Melanoma Program takes a team approach to the screening, early diagnosis, surgical management, and systemic therapy of melanoma from its earliest to most advanced stages. This multidisciplinary approach to all melanoma cases provides the best of care with a special emphasis on innovative therapies that are derived from cutting-edge research. The Vanderbilt-Ingram Cancer Center is the leading institution for melanoma care in the region, where more than 300 patients each year are evaluated or treated for melanoma. We are also committed to educating the medical community and public about the prevention and treatment of this disease.
Over the past few years, there has been a great expansion in the number of clinical trials offered to patients with early primary disease to high-risk resected disease to advanced unresectable disease. Clinical trials encompass options for all stages of the disease. For complete list of trials available at VICC, follow the link below: